Special Issue "Recent Advances in Immunotherapy for Solid Tumors"
Deadline for manuscript submissions: 30 November 2023 | Viewed by 1676
Interests: immunotherapy; translational research; immuno-oncology;preclinical study;clinical study;immune-monitoring; immune pProfiling; cancer vaccines;adoptive cell therapies
The special issue titled "Recent Advances in Immunotherapy for Solid Cancer" presents a comprehensive overview of research highlighting the latest breakthroughs in the immunotherapy for solid tumors. The issue brings together state of art technologies and studies that delve into various aspects of immunotherapy, including novel treatment approaches, combination strategies, biomarkers, and immune-related adverse events. This special issue focus on the remarkable progress made in harnessing the immune system to battle solid cancers. It covers a wide range of topics, including, but are not limited to adoptive cell therapies, immune checkpoint inhibitors, monoclonal antibodies, small molecules, cytokines, cancer vaccines, and oncolytic viruses. Moreover, the issue explores the role of the tumor microenvironment, neoantigens, and immune escape mechanisms in shaping the efficacy of immunotherapeutic interventions.
In addition, the special issue emphasizes the importance of personalized medicine in immunotherapy, with articles focusing on patient-specific approaches such as neoantigen identification, immune profiling, biomarkers, and targeted therapies. The integration of genomics, transcriptomics, proteomics and metabolomics in the development of personalized treatment strategies would be also highlighted as a key area of research.
Furthermore, the special issue addresses the challenges and opportunities associated with immunotherapy, including the management of immune-related adverse events, mechanisms of resistance, strategies for overcoming immunosuppression within the tumor microenvironment, and potency assessment of therapeutic approaches.
Dr. Satoko Matsueda
Dr. Yoshimi Arima
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- personalized medicine
- pharmacology study
- toxicology study
- immune-related adverse events
- tumor microenvironment
- immune escape
- immune profiling
- potency assessment
- combination therapy
- tumor biology
- molecular biology
- molecular pathology